Cancer cachexia, one of the metabolic syndromes caused by cancer, is a devastating and miserable
condition encountered in more than 50% of terminal cancer patients presenting with significant weight loss
associated with skeletal muscle atrophy and fat loss. Though cachexia may account for up to 20% of cancer
deaths, no significant treatment is still lacking and is of urgent unmet medical need in cancer treatment.
Therefore, understanding the underlying molecular mechanisms is essential for anticipating therapeutic
approaches. Since the primary events driving cachexia are mediated via either the central nervous system relatedor
inflammation related-anorexia, hypoanabolism, and hypercatabolism, therapy usually targets nutritional
support to compensate reduced food intake along with some anti-inflammatory agents to cover specific
inflammation-related metabolic derangement, and encourages exercise to supplement reduced physical activity,
but all proven to be not so effective so far. Therefore, combination therapies such as a standard multi-modal
package including an anorexic agent, megestrol acetate, and anti-inflammatory agent coupled with the
development of potential novel therapeutics promise a new era in rescuing patients from cancer cachexia. In this
review, we propose the potential application of BPC157, one of the active cytoprotective agents isolated from
gastric juices for cancer cachexia. Before clinical trial, we introduced the evidence showing BPC157 rescued
from cancer cachexia supported with explored mode of actions.